ATE217863T1 - Arylsulfonylaminohydroxamsäurederivate - Google Patents

Arylsulfonylaminohydroxamsäurederivate

Info

Publication number
ATE217863T1
ATE217863T1 AT98305959T AT98305959T ATE217863T1 AT E217863 T1 ATE217863 T1 AT E217863T1 AT 98305959 T AT98305959 T AT 98305959T AT 98305959 T AT98305959 T AT 98305959T AT E217863 T1 ATE217863 T1 AT E217863T1
Authority
AT
Austria
Prior art keywords
aryl
acid derivatives
arylsulfonylaminohydroxamic
arylsulfonylaminohydroxamic acid
angiogenisis
Prior art date
Application number
AT98305959T
Other languages
English (en)
Inventor
Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE217863T1 publication Critical patent/ATE217863T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
AT98305959T 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsäurederivate ATE217863T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5520897P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
ATE217863T1 true ATE217863T1 (de) 2002-06-15

Family

ID=21996365

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98305959T ATE217863T1 (de) 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsäurederivate

Country Status (9)

Country Link
EP (1) EP0895988B1 (de)
JP (1) JPH11116549A (de)
AT (1) ATE217863T1 (de)
BR (1) BR9803128A (de)
CA (1) CA2244501C (de)
DE (1) DE69805473T2 (de)
DK (1) DK0895988T3 (de)
ES (1) ES2176913T3 (de)
PT (1) PT895988E (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
WO2000058280A1 (fr) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
DE60003863T2 (de) * 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
BR0109328A (pt) * 2000-03-21 2003-06-10 Procter & Gamble Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
JP4008708B2 (ja) * 2000-04-07 2007-11-14 サムスン エレクトロニクス カンパニー リミテッド マトリックスメタロプロテイナーゼの阻害剤としてのスルホンアミド誘導体
ES2345977T3 (es) * 2001-03-14 2010-10-07 Novartis Ag Derivados de acido acetico azacicloalquil sustituidos para uso como inhibidores de mmp.
PL222211B1 (pl) 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
WO2003042176A1 (fr) * 2001-11-13 2003-05-22 Shiseido Co., Ltd. Compose azabicyclo, inhibiteur de metalloprotease matricielle et preparation cutanee
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2471814C (en) 2001-12-27 2011-03-15 Sumitomo Pharmaceuticals Co., Ltd. Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
CA2549598A1 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
CN1901971A (zh) 2003-12-15 2007-01-24 日本烟草产业株式会社 环丙烷化合物及其药物应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69511089T2 (de) * 1994-06-22 1999-12-16 British Biotech Pharm Metalloproteinase-inhibitoren
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6153609A (en) * 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives

Also Published As

Publication number Publication date
CA2244501A1 (en) 1999-02-08
EP0895988A1 (de) 1999-02-10
CA2244501C (en) 2003-03-18
PT895988E (pt) 2002-09-30
DE69805473T2 (de) 2003-01-16
DK0895988T3 (da) 2002-09-09
BR9803128A (pt) 2000-05-02
ES2176913T3 (es) 2002-12-01
EP0895988B1 (de) 2002-05-22
DE69805473D1 (de) 2002-06-27
JPH11116549A (ja) 1999-04-27

Similar Documents

Publication Publication Date Title
ATE217863T1 (de) Arylsulfonylaminohydroxamsäurederivate
EP0818442A3 (de) Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor
MY113586A (en) Aylsulfonylamino hydroxamic acid derivatives
CA2218503A1 (en) Arylsulfonyl hydroxamic acid derivatives
FR2744010B1 (fr) Procede de fabrication d'implants osseux
EA199900139A1 (ru) Производные арилсульфониламиногидроксамовой кислоты
WO2004024081A3 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
AP9801174A0 (en) Cyclic sulfone derivatives.
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
WO1991002716A3 (en) Hydroxamic acid based collagenase inhibitors
CA2343204A1 (en) Arylsulfonanilide ureas
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
WO2003007719A1 (en) Cleansers, cleansing system, bleaching agents and compositions for enviromental conservation
MX9707692A (es) Acido aza bisfosfonicos herbicidas y composiciones que los contienen.
BR9911010A (pt) Inibidores de sucinamida de enzima de conversão da interleucina-1beta
CA2254731A1 (en) Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
BR0100878A (pt) Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz
EP1152004A4 (de) Derivate der phosphonsäure zur inhibierung von carboxypeptidase b
TNSN05067A1 (en) Acetyl 2-hydroxy- 1,3 diaminoalkanes
WO2000015208A3 (en) New use of immunosupressants for mmp-mediated diseases
DK0826681T3 (da) Epoxyravsyrederivater
TW363056B (en) Inhibition of matrix metalloproteases by substituted phenethyl compounds
PL296314A2 (en) Method of obtaining novel derivatives of tridiazinones
CA2397960A1 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee